PLK1 Inhibition Sensitizes Breast Cancer Cells to Radiation via Suppressing Autophagy

被引:39
|
作者
Wang, Baiyao [1 ]
Huang, Xiaoting [1 ]
Liang, Huiping [1 ]
Yang, Hongli [2 ]
Guo, Zhaoze [3 ]
Ai, Meiling [1 ]
Zhang, Jian [1 ]
Khan, Muhammad [1 ]
Tian, Yunhong [1 ]
Sun, Quanquan [4 ]
Mao, Zixu [5 ]
Zheng, Ronghui [1 ]
Yuan, Yawei [1 ]
机构
[1] Guangzhou Med Univ, Dept Radiat Oncol, Affiliated Canc Hosp & Inst, Guangzhou, Guangdong, Peoples R China
[2] Shenzhen Peoples Hosp, Dept Radiat Oncol, Shenzhen, Guangdong, Peoples R China
[3] Southern Med Univ, Nanfang Hosp, Breast Ctr, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China
[4] Zhejiang Canc Hosp, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China
[5] Emory Univ, Sch Med, Dept Pharmacol & Chem Biol, Atlanta, GA USA
基金
中国国家自然科学基金;
关键词
KINASE; 1; PHASE-I; RADIORESISTANCE; PATHWAY; RADIOSENSITIZATION; CHEMOTHERAPY; VOLASERTIB; RESISTANT; CARCINOMA; ROS;
D O I
10.1016/j.ijrobp.2021.02.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Polo-like kinase 1 (PLK1) is a protein kinase that is overexpressed in breast cancer and may represent an attractive target for breast cancer treatment. However, few studies have investigated the relationship between PLK1 and radiosensitivity in breast cancer. Here, we attempted to explore whether PLK1 inhibition could sensitize breast cancer cells to radiation. Methods and Materials: Breast cancer cells were treated with PLK1 small interference RNA or the PLK1-inhibitor, GSK461364. Cell proliferation was assessed using a colony formation assay. Cell cycle analyses were performed by flow cytometry. DNA damage, autophagy, and reactive oxygen species induced by ionizing radiation were detected by immunofluorescence, Western blot, and flow cytometry, respectively. Microtubule-associated protein 1 light chain 3 alpha (LC3) puncta were detected using an immunofluorescence assay. A clonogenic survival assay was used to determine the effect of PLK1 inhibition on cell radiosensitivity. A xenograft mouse model of breast cancer cells was used to investigate the potential synergistic effects of PLK1 inhibition and irradiation in vivo. Finally, the expression of PLK1 and LC3 in the breast cancer tissues was evaluated by immunohistochemistry. Results: PLK1 inhibition significantly suppressed the proliferation and increased the radiosensitivity of breast cancer cells. Pharmacologic inhibition of PLK1 by the selective inhibitor, GSK461364, enhanced the radiosensitivity of breast cancer cells in vivo (n = 4, P = .002). Mechanistically, PLK1 inhibition led to the downregulation of radiation-induced reactive oxygen species and autophagy, thereby increasing the radiosensitivity of breast cancer cells. Additionally, we detected a positive correlation between the expression of PLK1 and LC3 in human breast cancer samples (n = 102, R = 0.486, P = .005). Conclusions: Our findings indicate that PLK1 inhibition enhances the radiosensitivity of breast cancer cells in a manner associated with the suppression of radiation-induced autophagy. The inhibition of PLK1 represents a promising strategy for radiosensitizing breast cancer. (C) 2021 The Authors. Published by Elsevier Inc.
引用
收藏
页码:1234 / 1247
页数:14
相关论文
共 50 条
  • [1] Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition
    Xi, Qian
    Kunita, Akiko
    Ogawa, Miho
    Ka, Mirei
    Tanimoto, Saki
    Tsuchimochi, Saki
    Nagai, Saeko
    Matsunaga, Asami
    Fukuda, Tomohiko
    Watanabe, Kousuke
    Sone, Kenbun
    Shinozaki-Ushiku, Aya
    Kawana, Kei
    Ushiku, Tetsuo
    Osuga, Yutaka
    Katayama, Kazuhiro
    Kage, Hidenori
    Oda, Katsutoshi
    ONCOGENE, 2025,
  • [2] Nrf2 inhibition sensitizes breast cancer stem cells to ionizing radiation via suppressing DNA repair
    Qin, Shenghui
    He, Xiaoyuan
    Lin, Houmin
    Schulte, Bradley A.
    Zhao, Mingfeng
    Tew, Kenneth D.
    Wang, Gavin Y.
    FREE RADICAL BIOLOGY AND MEDICINE, 2021, 169 : 238 - 247
  • [3] Polo-like Kinase 1 (PLK1) inhibition synergizes with docetaxel in basal breast cancer cells
    Giordano, A.
    Liu, Y.
    Armeson, K. E.
    Britten, C. D.
    Kappler, C. S.
    Ethier, S. P.
    CANCER RESEARCH, 2019, 79 (04)
  • [4] Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
    Ueda, Ai
    Oikawa, Keiki
    Fujita, Koji
    Ishikawa, Akio
    Sato, Eiichi
    Ishikawa, Takashi
    Kuroda, Masahiko
    Kanekura, Kohsuke
    LABORATORY INVESTIGATION, 2019, 99 (09) : 1275 - 1286
  • [5] Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
    Zhang, Zhuangzhuang
    Cheng, Lijun
    Li, Jie
    Qiao, Qi
    Karki, Anju
    Allison, Derek B.
    Shaker, Nuha
    Li, Kunyu
    Utturkar, Sagar M.
    Lanman, Nadia M. Atallah
    Rao, Xiongjian
    Rychahou, Piotr
    He, Daheng
    Konieczny, Stephen F.
    Wang, Chi
    Shao, Qing
    Evers, B. Mark
    Liu, Xiaoqi
    CANCER RESEARCH, 2022, 82 (19) : 3532 - 3548
  • [6] Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib
    Eggermont, Carolien
    Gutierrez, Gustavo J.
    De Greve, Jacques
    Giron, Philippe
    CANCERS, 2023, 15 (09)
  • [7] Combinatorial Effect of PLK1 Inhibition with Temozolomide and Radiation in Glioblastoma
    Pandey, Arvind
    Tripathi, Satyendra C.
    Mai, Junhua
    Hanash, Samir M.
    Shen, Haifa
    Mitra, Sankar
    Rostomily, Robert C.
    CANCERS, 2021, 13 (20)
  • [8] PLK1 inhibition in cancer therapy: potentials and challenges
    Elsayed, Inas
    Wang, Xiaosheng
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (12) : 1383 - 1386
  • [9] SOV sensitizes gastric cancer cells to radiation by suppressing radiation-induced autophagy in vitro and in vivo
    Wang, Wen
    Jiang, Xiao-gan
    Bai, Ya-ping
    Li, Heng
    Gao, Ling-xi
    Zhang, Teng
    Dong, Fang-yi
    Ding, Wen-ping
    Zhang, Yan
    TISSUE & CELL, 2023, 82
  • [10] Targeting PLK1 and PLK3 sensitizes cervical cancer to cisplatin-based chemoradiotherapy
    Gasimli, Khayal
    Raab, Monika
    Gasimli, Nurlana
    Rad, Morva Tahmasbi
    Becker, Sven
    Strebhardt, Klaus
    Sanhaji, Mourad
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 96 - 97